MANNKIND CORP Current Liabilities
MANNKIND CORP (MNKD) had Current Liabilities of $142.90 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:LiabilitiesCurrent · last filed 2026-08-05
- 2026-06-30: Liabilities, Current $142.90M.
- 2026-03-31: Liabilities, Current $134.56M.
- 2025-12-31: Liabilities, Current $171.03M.
- 2025-09-30: Liabilities, Current $109.13M.
| Period end | Liabilities, Current |
|---|---|
| 2026-06-30 | $142.90M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $134.56M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $171.03M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $109.13M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $111.83M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $115.94M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $81.84M 10-K · filed 2026-02-26 |
| 2024-09-30 | $72.10M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $80.01M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $99.90M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $104.13M 10-K · filed 2025-02-26 |
| 2023-09-30 | $96.37M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $96.97M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $81.85M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $67.30M 10-K · filed 2024-02-27 |
| 2022-09-30 | $59.60M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $59.56M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $53.49M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $48.35M 10-K · filed 2023-02-23 |
| 2021-09-30 | $50.03M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $60.43M 10-Q · filed 2021-08-11 |
| 2021-03-31 | $73.12M 10-Q · filed 2021-05-12 |
| 2020-12-31 | $73.70M 10-K · filed 2022-02-24 |
| 2020-09-30 | $106.12M 10-Q · filed 2020-11-04 |
| 2020-06-30 | $67.94M 10-Q · filed 2020-08-05 |
| 2020-03-31 | $68.25M 10-Q · filed 2020-05-06 |
| 2019-12-31 | $65.62M 10-K · filed 2021-02-25 |
| 2019-09-30 | $64.29M 10-Q · filed 2019-11-08 |
| 2019-06-30 | $76.98M 10-Q · filed 2019-08-07 |
| 2019-03-31 | $77.87M 10-Q · filed 2019-05-07 |
| 2018-12-31 | $75.24M 10-K · filed 2020-02-25 |
| 2018-09-30 | $59.63M 10-Q · filed 2018-11-01 |
| 2018-06-30 | $74.90M 10-Q · filed 2018-08-02 |
| 2018-03-31 | $80.67M 10-Q · filed 2018-05-09 |
| 2017-12-31 | $87.60M 10-K · filed 2019-02-26 |
| 2017-09-30 | $91.47M 10-Q · filed 2017-11-07 |
| 2017-06-30 | $85.87M 10-Q · filed 2017-08-07 |
| 2017-03-31 | $93.05M 10-Q · filed 2017-05-10 |
| 2016-12-31 | $92.05M 10-K · filed 2018-02-27 |
| 2016-09-30 | $105.83M 10-Q · filed 2016-11-09 |
| 2016-06-30 | $289.71M 10-Q/A · filed 2016-08-10 |
| 2016-03-31 | $249.21M 10-Q · filed 2016-05-09 |
| 2015-12-31 | $268.32M 10-K · filed 2017-03-16 |
| 2015-09-30 | $267.31M 10-Q · filed 2015-11-09 |
| 2015-06-30 | $342.25M 10-Q · filed 2015-08-10 |
| 2015-03-31 | $380.75M 10-Q · filed 2015-05-11 |
| 2014-12-31 | $403.35M 10-K · filed 2016-03-15 |
| 2014-09-30 | $293.78M 10-Q · filed 2014-11-10 |
| 2014-06-30 | $119.23M 10-Q · filed 2014-08-11 |
| 2014-03-31 | $44.52M 10-Q · filed 2014-05-12 |
| 2013-12-31 | $127.79M 10-K · filed 2015-03-02 |
| 2013-09-30 | $217.17M 10-Q · filed 2013-11-12 |
| 2013-06-30 | $266.78M 10-Q · filed 2013-08-09 |
| 2013-03-31 | $264.21M 10-Q · filed 2013-05-10 |
| 2012-12-31 | $144.78M 10-K · filed 2014-03-03 |
| 2012-09-30 | $51.76M 10-Q · filed 2012-11-09 |
| 2012-06-30 | $55.44M 10-Q · filed 2012-08-09 |
| 2012-03-31 | $34.41M 10-Q · filed 2012-05-10 |
| 2011-12-31 | $25.36M 10-K · filed 2013-03-18 |
| 2011-09-30 | $17.31M 10-Q · filed 2011-11-04 |
| 2011-06-30 | $21.56M 10-Q · filed 2011-08-04 |
| 2010-12-31 | $18.13M 10-K · filed 2012-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |